Cimetidine Cancer Research Results

Cim, Cimetidine: Click to Expand ⟱
Features:

Cimetidine (Tagamet) — A synthetic, orally active imidazole-derived histamine H2-receptor antagonist (H2RA) originally developed to suppress gastric acid secretion. Classified as a pharmaceutical drug with investigational anticancer and immunomodulatory applications, it is commonly abbreviated CIM. Its principal oncology mechanisms involve reversal of histamine-mediated immunosuppression and inhibition of endothelial E-selectin-dependent tumour-cell adhesion, potentially limiting hematogenous metastasis. Cimetidine also exhibits context-dependent antiproliferative and antiangiogenic effects. Unlike some other H2 antagonists, cimetidine has demonstrated E-selectin inhibitory activity apparently independent of H2-receptor blockade. Its strongest oncology evidence concerns adjunctive treatment around colorectal cancer surgery.

Primary mechanisms (ranked):

  1. Histamine H2-receptor antagonism: Blocks histamine-mediated H2R signalling, reducing gastric acid secretion and potentially reversing histamine-dependent tumour-associated immunosuppression.
  2. Antimetastatic E-selectin inhibition: ↓ Endothelial surface E-selectin expression and ↓ adhesion of circulating tumour cells expressing sialyl Lewis-X or sialyl Lewis-A antigens. This action appears partly independent of H2R antagonism.
  3. Antitumour immune modulation: ↑ NK-cell and cytotoxic T-cell activity, improved antigen-presenting function, and attenuation of histamine-associated Treg-mediated immune suppression (context-dependent).
  4. Th1/Th2 cytokine modulation: Potential ↑ IL-12, ↓ IL-10 and restoration of cell-mediated antitumour immunity in histamine-responsive models.
  5. Perioperative immune preservation: May reduce surgery-associated suppression of lymphocyte proliferation and cell-mediated immunity, potentially improving immune surveillance during the postoperative period.
  6. Direct antiproliferative effects: Inhibition of histamine-dependent tumour growth signalling, with apoptosis reported in selected cancer models; not established as a universal or clinically dominant mechanism.
  7. Angiogenesis modulation: Possible reduction of proangiogenic signalling and tumour vascularization in selected preclinical models; secondary and model-dependent.
  8. Androgen-receptor antagonism: Weak antiandrogenic activity, associated with endocrine adverse effects; not an established anticancer mechanism at standard human exposures.

Bioavailability / PK relevance: Cimetidine is orally absorbed, with peak plasma concentrations generally occurring 45–90 minutes after administration and an elimination half-life of approximately 2 hours. Renal excretion is important, and dosage adjustment is required in significant renal impairment. Historical colorectal cancer trials frequently used 800 mg/day, although protocols varied. Cimetidine inhibits the metabolism of numerous drugs and has clinically important interactions with warfarin, phenytoin, theophylline, propranolol and other medications.

In-vitro vs systemic exposure relevance: Histamine H2-receptor blockade is achievable at conventional therapeutic exposure. However, direct anticancer effects reported at high experimental concentrations cannot automatically be extrapolated to clinical dosing. The concentration dependence and clinical attainability of endothelial E-selectin inhibition require further validation. In-vitro antiproliferative activity may exceed achievable systemic exposure depending on the model and experimental conditions.

Clinical evidence status: RCT / Adjunct use / Preclinical. Multiple historical randomized studies evaluated cimetidine around colorectal cancer surgery. A Cochrane analysis of five cimetidine trials involving 421 patients reported improved overall survival (HR 0.53; 95% CI 0.32–0.87), but study heterogeneity, small sample sizes and outdated treatment protocols limit certainty. One 64-patient study reported substantial long-term survival differences when cimetidine was added to postoperative 5-fluorouracil, particularly in tumours expressing high levels of sialyl Lewis antigens. These findings remain hypothesis-generating. Cimetidine is not an established or approved anticancer therapy.

Cimetidine — Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Histamine H2R Signalling ↓ H2R-mediated proliferative signalling (context-dependent) ↓ H2R signalling in gastric parietal and immune cells R H2-receptor antagonism Established pharmacological mechanism; antitumour consequences depend on histamine sensitivity and tumour microenvironment.
2 E-selectin / Sialyl Lewis Adhesion ↓ Endothelial adhesion and metastatic attachment ↓ Endothelial surface E-selectin R/G Antimetastatic adhesion inhibition Particularly relevant to colorectal tumours expressing sLeX or sLeA. Effect appears partly H2R-independent and is supported by experimental metastasis models.
3 NK Cells / Cytotoxic T-cell Immunity ↑ Immune-mediated tumour-cell elimination (context-dependent) ↑ NK and effector T-cell function (context-dependent) G Restoration of antitumour surveillance Reversal of histamine-associated immune suppression; human perioperative studies support immune preservation but not all specific cellular mechanisms.
4 Treg / Immunosuppressive Microenvironment ↓ Immune escape (indirect) ↓ Histamine-associated regulatory suppression (context-dependent) G Immunomodulation Effects on FoxP3-associated Treg activity and suppressive immune populations are model-dependent; evidence is predominantly experimental.
5 IL-12 / IL-10 / Th1–Th2 Balance ↑ Cell-mediated antitumour response (indirect) ↑ IL-12; ↓ IL-10; ↑ Th1-associated activity (context-dependent) G Proimmune cytokine modulation Reverses selected histamine-mediated cytokine responses. Not a demonstrated universal systemic cytokine effect.
6 Perioperative Immune Suppression ↓ Opportunity for immune escape (indirect) ↑ Preservation of lymphocyte proliferation and cell-mediated immunity G Postoperative immune preservation Small randomized colorectal surgery studies reported attenuation of postoperative immune suppression.
7 Proliferation / Apoptosis ↓ Proliferation; ↑ apoptosis (model-dependent) ↔ Variable G Direct tumour-growth inhibition Reported in selected cancer cell lines. Some effects may be H2R-independent; pharmacologically achievable exposure remains uncertain.
8 Angiogenesis / VEGF-associated Signalling ↓ Angiogenic support (model-dependent) ↓ Proangiogenic signalling (model-dependent) G Potential antiangiogenic activity Secondary preclinical mechanism; insufficient evidence to establish direct VEGF inhibition as a principal human effect.
9 Androgen Receptor Signalling ↓ Androgen signalling (weak; context-dependent) ↓ Androgen receptor activity G Weak antiandrogenic action Pharmacologically relevant to gynecomastia and other endocrine adverse effects; clinical antitumour leverage is unproven.
10 Drug Metabolism / CYP Inhibition ↔ Indirect effects through altered drug exposure ↓ Hepatic metabolism of multiple medications R/G Pharmacokinetic interactions Clinically significant interaction potential, including with anticoagulants, anticonvulsants, beta-blockers and some oncology drugs. Not equivalent to proven chemosensitization.
11 Clinical Translation Constraint ↔ Response varies by tumour type and adhesion-marker expression ↑ Drug exposure in renal impairment; possible CNS and endocrine adverse effects R/G Limits clinical application Historical small RCTs, uncertain modern treatment benefit, limited mechanistic PK validation and substantial drug-interaction potential. No established oncology dosing protocol.

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr



Scientific Papers found: Click to Expand⟱
9116- Cim,    Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells
- Trial, CRC, NA
eff↑, Dose↝, OS↑, E-sel↓, TumCA↓,
9117- Cim,    Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression
- vitro+vivo, CRC, NA
OS↑, TumCA↓, TumMeta↓, E-sel↑,
9118- Cim,    Cimetidine inhibits angiogenesis and suppresses tumor growth
- vitro+vivo, CRC, NA
OS↑, angioG↓,
9119- Cim,    An interesting change of E-selectin in cimetidine administration during anticancer drug use
- in-vitro, GC, NA - in-vitro, CRC, NA
E-sel↓,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Migration(tgid=13) ⓘ

TumCA↓, 2,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   E-sel↓, 2,   E-sel↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 1,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 3,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:513  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page